Prediction of coronary risk for primary prevention of coronary heart disease: A comparison of methods

QJM: An International Journal of Medicine

Volumn 92, Issue 7, 1999, Pages 379-385

  Haq, I U ^a   Ramsay, L E ^a   Jackson, P R ^a   Wallis, E J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ACCURACY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0032768536     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.7.379     Document Type: Article

References (34)

1. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19:1434-503.
2. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SC. Primary prevention of coronary heart disease: guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on risk reduction. Circulation 1998; 97:1876-87.
3. Unwin N, Thomson R, O'Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. Br Med J 1998; 317:1125-30.
4. Betteridge D, Dodson P, Durrington P, Hughes E, Laker M, Nicholls D, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69:359-69.
5. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the task force. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15:1300-31.
6. National Cholesterol Education Programme. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel 2). Circulation 1994; 89:1333-45.
7. Standing Medical Advisory Committee. The use of statins. London, Standing Medical Advisory Committee 1997.
8. Fahey T. Assessing heart disease risk in primary care. Cholesterol lowering should be just one part of a multiple risk factor intervention. Br Med J 1998; 317:1093-4.
9. Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for the prevention of coronary heart disease: what policy now? Clin Sci 1996; 91:399-413.
10. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348:387-8.
11. NHS Centre for Reviews and Dissemination, University of York. Cholesterol and coronary heart disease: screening and treatment. Effective Health Care 1998; 4:1-16.
12. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-9.
13. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-42.
14. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
15. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346:1467-71.
16. Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS. Air Force/Texas Coronary Atherosclerosis Study. JAMA 1998; 279:1615-22.
17. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-8
18. Dyslipidaemia Advisory Group on behalf of the scientific committee of The National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. N Z Med J 1996; 109:224-32.
19. Haq IU, Jackson PR, Yeo WW, Ramsay LE. A comparison of methods for targeting CHD risk for primary prevention. Heart 1997; 77(Suppl 1):36.
20. Assman G, ed. Results and conclusions of the prospective cardiovascular Münster (PROCAM) Study. In: Lipid metabolism disorders and coronary heart disease: primary prevention, diagnosis and therapy guidelines for general practice. München, MMV-Medizin-Verlag, 1993.
21. Armitage P, Berry G. Statistical methods in medical research, 2nd edn. Oxford, Blackwell Scientific, 1987.
22. Raine R, Streetly A, Davis AM. Variation in local policies and guidelines for cholesterol management: national survey. Br Med J 1996; 313:1368-9.
23. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274:801-6.
24. Grover SA, Lowensteyn I, Esrey KL, Steinart Y, Joseoph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. Br Med J 1995; 310:975-8
25. Evans J ST BT, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br Med J 1994; 45:15-18.
26. Monthly Index of Medical Specialities. December 1998.
27. Avins AL, Browner WS. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels. What a difference a decade makes. JAMA 1998; 279:445-9.
28. Durrington PN, Prais H, Bhatnagar D, France M, Cowley V, Khan J, Morgan J. Indication for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999; 353:278-81.
29. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82:61-5.
30. Greenland P, Grundy S, Pasternak RC, Lenfant C. Problems on the pathway from risk assessment to risk reduction. Circulation 1998; 97:1761-2.
31. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40-6.
32. Kinosian B, Glick H, Preiss L, Puder KL. Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios. J Invest Med 1995; 43:443-50.
33. Bayly GR, Haddon A, Bartlett WA, Jones AF. Laboratory based calculation of coronary heart disease risk - a simple and accurate method of targeting primary prevention. Proc Roy Coll Phys Edin 1999; in press.
34. Freemantle N, Barbour R, Johnson R, Marchment M, Kennedy A. The use of statins: a case of misleading priorities? National guidance that does not link costs and benefits is worthless. Br Med J 1997; 315:826-8.